Pacific Biosciences of California (PACB) Shares are Down -1.86%

Pacific Biosciences of California (PACB) has risen sharply, recording gains of 8.21% in the past 4 weeks. However, the stock has corrected -1.86% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 8.8% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 2.85% and the 50-Day Moving Average is 4.94%.The 200 Day SMA reached 3.52%

Pacific

Pacific Biosciences of California (NASDAQ:PACB): After opening at $8.89, the stock dipped to an intraday low of $8.76 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $9.08 and the buying power remained strong till the end. The stock closed at $8.96 for the day, a gain of 1.59% for the day session. The total traded volume was 678,178. The stocks close on the previous trading day was $8.96.

Pacific Biosciences of California (PACB) : The consensus price target for Pacific Biosciences of California (PACB) is $12.75 for the short term with a standard deviation of $3.5. The most optimist securities analyst among the 4 who monitor the stock believes that the stock can reach $18, however, the pessimist price target for the company is $11.

Pacific Biosciences of California Inc. designs, develops and manufactures the PacBio RS II Sequencing System to help scientists resolve genetically complex problems. Based on the Companys Single Molecule, Real-Time (SMRT) technology, its products enable de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms and find genes; targeted sequencing to more comprehensively characterize genetic variations; and DNA (deoxyribonucleic acid) base modification identification to help characterize epigenetic regulation and DNA damage. SMRT enables single molecule, real-time detection of biological processes. Based on its SMRT technology, the Company introduced the PacBio RS II System to address many of the limitations.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.